AML
Haematology · 2017–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| liposomal daunorubicin with cytarabine Treatment of newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) in… | Apr 2024 | Recommended with restriction | no section in document |
| daunorubicin with cytarabine Treatment of newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) in adults… | Jul 2023 | Not recommended | input received Rare Cancers Australia · Leukaemia Foundation |
| daunorubicin with cytarabine Treatment of newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) in adults. | Nov 2023 | Recommended with restriction | input received |
| azacitidine Maintenance therapy in patients with acute myeloid leukaemia (AML) who achieve complete remission (CR) or complete remission with incomplete blood count… | Jul 2022 | Not recommended | 2 individuals Leukaemia Foundation |
| gilteritinib Treatment of patients with relapsed or refractory acute myeloid leukaemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation. | Mar 2022 | Recommended with restriction | input received Rare Cancers Australia · Leukaemia Foundation · Lymphoma Group |
| venetoclax Treatment of patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard intensive remission induction chemotherapy, in… | Jul 2021 | Recommended with restriction | 1 individuals Leukaemia Foundation |
| gemtuzumab ozogamicin Previously untreated, de novo CD33-positive acute myeloid leukaemia (except acute promyelocytic leukaemia) in combination with standard intensive chemotherapy… | Mar 2021 | Not recommended | input received Leukaemia Foundation · Rare Cancers Australia |
| venetoclax Treatment of patients with newly diagnosed acute myeloid leukaemia (AML), ineligible for standard intensive remission induction chemotherapy, given in… | Mar 2021 | Not recommended | input received Leukaemia Foundation · Rare Cancers Australia |
| gemtuzumab ozogamicin Previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia, with favourable/intermediate/unknown… | Nov 2021 | Recommended with restriction | input received Leukaemia Foundation · Rare Cancers Australia · Lymphoma Group |
| gilteritinib Treatment of patients with relapsed or refractory acute myeloid leukaemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation. | Nov 2021 | Not recommended | input received Leukaemia Foundation |
| midostaurin Treatment of FMS-like tyrosine kinase-3 (FLT3) mutation positive acute myeloid leukaemia (AML) in newly diagnosed patients eligible for standard intensive… | Jul 2018 | Recommended with restriction | none received |
| midostaurin Treatment of FLT3 mutation positive acute myeloid leukaemia (AML) in newly diagnosed patients eligible for standard intensive remission induction chemotherapy. | Nov 2017 | Not recommended | none received |
Who spoke
Leukaemia Foundation · Rare Cancers Australia · Lymphoma Group
What the PBS pays
$123M in government benefit over 2024–25, across 50,017 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| venetoclax | $77.2M |
| gilteritinib | $13.6M |
| azacitidine | $11.3M |
| midostaurin | $10.7M |
| daunorubicin with cytarabine | $4.2M |
| liposomal daunorubicin and cytarabine | $4.2M |
| daunorubicin with cytarabine (liposomal) | $1.2M |
| gemtuzumab ozogamicin | $0.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 14 technologies for this condition, recommending 9 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| quizartinibQuizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | recommended | 2024-10 |
| ivosidenibIvosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | recommended restricted | 2024-06 |
| decitabine cedazuridineDecitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | terminated | 2023-11 |
| oral azacitidineOral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | recommended | 2022-10 |
| venetoclaxVenetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | recommended restricted | 2022-04 |
| venetoclaxVenetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | recommended restricted | 2022-02 |
| glasdegibGlasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | terminated | 2020-09 |
| gilteritinibGilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | recommended restricted | 2020-08 |
| liposomal cytarabine daunorubicinLiposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | recommended restricted | 2018-12 |
| decitabineDecitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | terminated | 2018-12 |
| gemtuzumab ozogamicinGemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | recommended restricted | 2018-11 |
| midostaurinMidostaurin for untreated acute myeloid leukaemia | TA523 | recommended restricted | 2018-06 |
Showing the 12 most recent of 14.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| idarubicinIDARUBICIN EBEWE idarubicin hydrochloride 10mg/10mL concentrated injec | 1999 | 7 |
| mitozantroneMITOZANTRONE EBEWE mitozantrone (as hydrochloride) 10mg/5mL solution f | 2001 | 6 |
| tioguanineLANVIS tioguanine 40mg tablet bottle | 1991 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 9 of 12 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.